Since breast cancer is notable for the high incidence of cyclin D1 aberrations with up to 50% of tumors expressing elevated levels of the protein (reviewed in [59], [59], [62]), we can expect to find p16 defects among the remaining tumors. This evidence concerns the gene CDKN2A and breast cancer.